These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 30861353

  • 1. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.
    Liang H, Xu Y, Zhang Q, Yang Y, Mou Y, Gao Y, Chen R, Chen C, Dai P.
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):725-736. PubMed ID: 30861353
    [Abstract] [Full Text] [Related]

  • 2. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
    Wu YZ, Lin HY, Zhang Y, Chen WF.
    J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
    [Abstract] [Full Text] [Related]

  • 3. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W, Li J, Zhou L, Han J, Liu R, Zhang H, Ning T, Gao Z, Liu B, Chen X, Ba Y.
    Theranostics; 2020 Jul; 10(5):1981-1996. PubMed ID: 32104496
    [Abstract] [Full Text] [Related]

  • 4. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
    Liu T, Zhang X, Du L, Wang Y, Liu X, Tian H, Wang L, Li P, Zhao Y, Duan W, Xie Y, Sun Z, Wang C.
    Mol Cancer; 2019 Mar 19; 18(1):43. PubMed ID: 30890168
    [Abstract] [Full Text] [Related]

  • 5. miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells.
    Rasmussen MH, Lyskjær I, Jersie-Christensen RR, Tarpgaard LS, Primdal-Bengtson B, Nielsen MM, Pedersen JS, Hansen TP, Hansen F, Olsen JV, Pfeiffer P, Ørntoft TF, Andersen CL.
    Nat Commun; 2016 Aug 16; 7():12436. PubMed ID: 27526785
    [Abstract] [Full Text] [Related]

  • 6. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
    Wang H, Li H, Zhang L, Yang D.
    Biomed Pharmacother; 2018 Oct 16; 106():1607-1615. PubMed ID: 30119236
    [Abstract] [Full Text] [Related]

  • 7. The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
    Hu J, Cai G, Xu Y, Cai S.
    Curr Mol Med; 2016 Oct 16; 16(1):70-82. PubMed ID: 26695693
    [Abstract] [Full Text] [Related]

  • 8. Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p.
    Ghanbarian M, Afgar A, Yadegarazari R, Najafi R, Teimoori-Toolabi L.
    Biomed Pharmacother; 2018 Dec 16; 108():1070-1080. PubMed ID: 30372807
    [Abstract] [Full Text] [Related]

  • 9. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
    Hua Y, Zhu Y, Zhang J, Zhu Z, Ning Z, Chen H, Liu L, Chen Z, Meng Z.
    Cell Physiol Biochem; 2018 Dec 16; 51(5):2148-2159. PubMed ID: 30522111
    [Abstract] [Full Text] [Related]

  • 10. SIRT1 enhances oxaliplatin resistance in colorectal cancer through microRNA-20b-3p/DEPDC1 axis.
    Zhao B, Wang Y, Zhao X, Ni J, Zhu X, Fu Y, Yang F.
    Cell Biol Int; 2022 Dec 16; 46(12):2107-2117. PubMed ID: 36200529
    [Abstract] [Full Text] [Related]

  • 11. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
    Xiao Z, Liu Y, Li Q, Liu Q, Liu Y, Luo Y, Wei S.
    Cancer Chemother Pharmacol; 2021 Dec 16; 88(6):1021-1031. PubMed ID: 34599680
    [Abstract] [Full Text] [Related]

  • 12. Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer.
    Xu Y, Zhu M.
    Clin Transl Oncol; 2020 Jul 16; 22(7):1105-1116. PubMed ID: 31728833
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of microRNA-21-3p suppresses proliferation as well as invasion and induces apoptosis by targeting RNA-binding protein with multiple splicing through Smad4/extra cellular signal-regulated protein kinase signalling pathway in human colorectal cancer HCT116 cells.
    Hou N, Guo Z, Zhao G, Jia G, Luo B, Shen X, Bai Y.
    Clin Exp Pharmacol Physiol; 2018 Jul 16; 45(7):729-741. PubMed ID: 29542167
    [Abstract] [Full Text] [Related]

  • 14. miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses.
    Jiang T, Ye L, Han Z, Liu Y, Yang Y, Peng Z, Fan J.
    J Exp Clin Cancer Res; 2017 Sep 22; 36(1):131. PubMed ID: 28938919
    [Abstract] [Full Text] [Related]

  • 15. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
    Gao R, Fang C, Xu J, Tan H, Li P, Ma L.
    Arch Biochem Biophys; 2019 Mar 15; 663():183-191. PubMed ID: 30639170
    [Abstract] [Full Text] [Related]

  • 16. Tumor suppressor circPDE4D inhibits the progression of colorectal cancer and regulates oxaliplatin chemoresistance.
    Li J, Lv J, Chen Y, Li L.
    Gene; 2023 May 15; 864():147323. PubMed ID: 36858188
    [Abstract] [Full Text] [Related]

  • 17. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
    Zhou H, Lin C, Zhang Y, Zhang X, Zhang C, Zhang P, Xie X, Ren Z.
    Cell Prolif; 2017 Jun 15; 50(3):. PubMed ID: 28217977
    [Abstract] [Full Text] [Related]

  • 18. MiR-744 mediates the Oxaliplatin chemoresistance in colorectal cancer through inhibiting BIN1.
    Zhou Y, He A, Zhang L, Yi G.
    Neoplasma; 2020 Mar 15; 67(2):296-303. PubMed ID: 31884801
    [Abstract] [Full Text] [Related]

  • 19. miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L.
    Lv L, Li Q, Chen S, Zhang X, Tao X, Tang X, Wang S, Che G, Yu Y, He L.
    Exp Cell Res; 2019 Dec 01; 385(1):111597. PubMed ID: 31525340
    [Abstract] [Full Text] [Related]

  • 20. Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer.
    Lv Z, Wei J, You W, Wang R, Shang J, Xiong Y, Yang H, Yang X, Fu Z.
    J Transl Med; 2017 Dec 19; 15(1):257. PubMed ID: 29258530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.